JAMA Oncology

For localized deficient mismatch repair or microsatellite instability–high #GastricCancer and gastroesophageal junction adenocarcinoma, neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival. ja.ma/4ex2nGw

💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring. ja.ma/4hVydhi

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and disease control, with no muscle-invasive or metastatic progression during follow-up. ja.ma/4j8TEO5

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up. ja.ma/479i4jj

Among patients with #HepatocellularCarcinoma beyond the Milan criteria who underwent #LiverTransplant, an immune checkpoint inhibitor–based pretransplant strategy was associated with better survival and lower recurrence vs therapy without immune checkpoint inhibitors. ja.ma/4hFlgbb

Among patients with nonmetastatic #HeadNeckCancer receiving radiation therapy, financial toxicity was associated with worse quality of life and substantial out-of-pocket expenses. ja.ma/4dzMI8Z

This review examines ovarian metastases from colorectral cancer and the potential role of surgical resection of metastatic disease. ja.ma/4iKDA4S

Among adults in China and the UK, modifiable lifestyle factors and health conditions accounted for most of the male-female #Cancer incidence gap in China but only a smaller fraction in the UK. ja.ma/4ygALxm

In a recent @jamaoncology.com publication, @biagioricciutimd.bsky.social and @danafarber.bsky.social researchers found that first-line chemo-immunotherapy improved survival outcomes compared with PD-(L)1 inhibitor monotherapy in advanced NSCLC with PD-L1 ≥50%. Read more: bit.ly/4vVbhVh

We present a new type of biomarker - based on a math equation rather than a genetic or transcriptomic assay. By capturing dynamic patterns in PSA during the first treatment cycle, we can predict prostate cancer outcomes across disease settings, paving the way for personalized treatment schedules.

Writing in JAMA Oncology, YSM researchers report that prostate-specific membrane antigen positron emission tomography (PSMA-PET) #imaging could shift #prostate #cancer treatment patterns by detecting previously hidden metastases. @jamaoncology.com Learn more: medicine.yale.edu/publication-...

Prebiopsy #MRI use before #ProstateCancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. ja.ma/4gPW16U

Editorial: In HPV 16–positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. ja.ma/4xW1IWP

Meta-analysis: In #HeadAndNeckCancer with programmed cell death 1 ligand 1 combined positive score <1, #ImmuneCheckpointInhibitors were likely associated with reduced survival, including significantly reduced overall survival in recurrent or metastatic disease. ja.ma/46uMnAC

In #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. ja.ma/4xVtvql

In persistent, recurrent, or metastatic #CervicalCancer, first-line #Pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. ja.ma/3UHjheC

A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis? ja.ma/4cvl6kY

Among children with relapsed or refractory #BCellAcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with high rates of minimal residual disease–negative remission and durable event-free survival. ja.ma/4hc7VYK

Among patients with #ERBB2-positive #BreastCancer, neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with similar grade 3 or 4 toxic effects. ja.ma/46FBax8

💬 Editorial: In pediatric #AcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with durable remission despite limited persistence, challenging the view that prolonged CAR T-cell surveillance is always required. ja.ma/464VxDP

📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3SPjlZi

📑 This JAMA Oncology review discusses #Chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #BreastCancer. ja.ma/4x96mzy

In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. ja.ma/4ig46mA

#ColorectalCancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. ja.ma/4ymxIDm

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/3TbzUyG

In Denmark, #Meningioma incidence increased from 2010 to 2023, but #Surgery and #Radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment. ja.ma/465TUFZ

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/3TgzIhF

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4wVRi9f

Among patients with early #TripleNegativeBreastCancer, tissue-free #ctDNA detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. ja.ma/3S5A0Hu

Among men with #ProstateCancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, #MetabolicSyndrome and related abnormalities were frequently documented early, with hypertension the most common outcome. ja.ma/3TW65Cf

Among patients with metastatic #BreastCancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference. ja.ma/4xzjmPF

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/3UsSpyJ

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/4wjlR7I

In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/4wbDsyf

Among patients with metastatic #BreastCancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference. ja.ma/4hmHGPX

Among patients with metastatic #BreastCancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference. ja.ma/4bxDWHQ

In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/4cahe8J

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/4wq74ZI

💬 Viewpoint: In #Oncology, payment incentives may shape the context of care recommendations, and directional disclosure of those incentives deserves consideration as part of informed consent. ja.ma/4x8ET1B

In a phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells for diffuse large B-cell lymphoma, 92% of adults had objective responses and most toxicities were grade 1-2, supporting further evaluation of cytokine-engineered CAR T strategies. ja.ma/4fk0oGA

Among adults with #obesity, use of #GLP-1 receptor agonists was associated with reduced risk of endometrial, ovarian, and meningioma cancers and a slight increase in kidney #cancer risk. 📖 Read the full article for more details: ja.ma/4hdC2Q4

In metastatic breast cancer trials, progression-free survival by blinded central review and investigator assessment was similar, supporting use of either method for endpoint evaluation. ja.ma/4w2Lcn4

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. ja.ma/4vjZWNb

Among patients with advanced #BiliaryTractCancer, durvalumab plus gemcitabine and cisplatin provided sustained 4-year overall survival benefit and a comparable safety profile vs placebo plus chemotherapy ja.ma/4ygxazN

Genomic profiling of consecutive meningiomas found associations between copy number alterations, somatic variants, tumor grade, and patient characteristics, offering insights into prognosis and therapeutic vulnerability. ja.ma/3SGkCRU

Patients with platinum-sensitive recurrent #OvarianCancer and exceptional response to PARP inhibitors showed ≥78% ten-year progression-free survival, with low risk of myeloid cancers, regardless of maintenance duration. ja.ma/44AA3h3

The 9-valent #HPV vaccine was linked to reduced risk of #HPVRelatedCancers in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. ja.ma/4uPlDod

Pretreatment MRI findings including extraprostatic extension and seminal vesicle invasion were independently prognostic for recurrence, metastasis, and mortality after radical prostatectomy. #ProstateCancer ja.ma/4xGq5Ii

Clonal hematopoiesis of indeterminate potential (CHIP) was associated with higher risk of trastuzumab-related cardiotoxicity and heart failure in patients with #BreastCancer. ja.ma/446aHaZ

Among adults with lymphoma or myeloma, second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy occurred in 3.5%, with most second primary malignant neoplasms being skin or hematologic cancers. ja.ma/3SlsYOG